Journal
CANCER DISCOVERY
Volume 3, Issue 2, Pages 145-147Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0585
Keywords
-
Categories
Ask authors/readers for more resources
Twenty-five years after the publication of seminal studies showing that HER2 gene amplification and protein overexpression are oncogenic in breast cancer, Bose and colleagues report on the identification of activating HER2 somatic mutations that, albeit rare, may determine the response of breast cancer cells to anti-HER2 agents. These results herald a new era for the potential use of existing HER2-targeted agents for the treatment of patients with HER2-mutant breast cancer. Cancer Discov; 3(2); 145-7. (C) 2012 AACR. See related article by Bose et al., p. 224 (7)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available